Galectin-1 as a potential diagnostic biomarker in polycystic ovary syndrome

Eur Rev Med Pharmacol Sci. 2023 Mar;27(6):2543-2551. doi: 10.26355/eurrev_202303_31788.

Abstract

Objective: This study was aimed at comparing the routine laboratory parameters and Galectin-1 levels of control and polycystic ovarian syndrome patients.

Patients and methods: 88 patients diagnosed with polycystic ovary syndrome and 88 healthy controls were considered for the study. Age groups of the patients ranged from 18 to 40. Serum TSH, Beta HCG, glucose, insulin, HOMA-IR, Hb1A1c, triglyceride, total cholesterol, LDL FSH, LH, E2, prolactin, testosterone, SHBG, DHESO4, HDL, Gal-1 levels were analyzed for each subject.

Results: FSH, LH, LH/FSH, E2, prolactin, testosterone, SHBG, DHESO4, HDL and Gal-1 values of the subjects included in the study were statistically significantly different between the groups (p<0.05). Gal-1 and DHESO4 showed a strong positive connection (p=0.05). The sensitivity of Gal-1 level in PCOS patients was calculated as 0.997 and specificity as 0.716.

Conclusions: High levels of Gal-1 in PCOS patients suggest that it increases due to overexpression in response to inflammation.

MeSH terms

  • Biomarkers
  • Body Mass Index
  • Female
  • Follicle Stimulating Hormone
  • Galectin 1
  • Humans
  • Insulin
  • Insulin Resistance* / physiology
  • Polycystic Ovary Syndrome* / diagnosis
  • Prolactin
  • Testosterone

Substances

  • Biomarkers
  • Follicle Stimulating Hormone
  • Galectin 1
  • Insulin
  • Prolactin
  • Testosterone